JP2005538129A5 - - Google Patents

Download PDF

Info

Publication number
JP2005538129A5
JP2005538129A5 JP2004527183A JP2004527183A JP2005538129A5 JP 2005538129 A5 JP2005538129 A5 JP 2005538129A5 JP 2004527183 A JP2004527183 A JP 2004527183A JP 2004527183 A JP2004527183 A JP 2004527183A JP 2005538129 A5 JP2005538129 A5 JP 2005538129A5
Authority
JP
Japan
Prior art keywords
cpt
capecitabine
topotecan
adriamycin
gemcitabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004527183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005538129A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/003388 external-priority patent/WO2004014386A1/en
Publication of JP2005538129A publication Critical patent/JP2005538129A/ja
Publication of JP2005538129A5 publication Critical patent/JP2005538129A5/ja
Withdrawn legal-status Critical Current

Links

JP2004527183A 2002-08-07 2003-07-28 erbBキナーゼ阻害剤および抗腫瘍療法の治療的組合せ Withdrawn JP2005538129A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40170502P 2002-08-07 2002-08-07
US46224703P 2003-04-11 2003-04-11
PCT/IB2003/003388 WO2004014386A1 (en) 2002-08-07 2003-07-28 Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies

Publications (2)

Publication Number Publication Date
JP2005538129A JP2005538129A (ja) 2005-12-15
JP2005538129A5 true JP2005538129A5 (enExample) 2006-09-14

Family

ID=31720553

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004527183A Withdrawn JP2005538129A (ja) 2002-08-07 2003-07-28 erbBキナーゼ阻害剤および抗腫瘍療法の治療的組合せ

Country Status (17)

Country Link
US (2) US20040067942A1 (enExample)
EP (1) EP1549320A1 (enExample)
JP (1) JP2005538129A (enExample)
CN (1) CN1674908A (enExample)
AR (1) AR040792A1 (enExample)
AU (1) AU2003249450A1 (enExample)
BR (1) BR0313470A (enExample)
CA (1) CA2494270A1 (enExample)
IL (1) IL166423A0 (enExample)
MX (1) MXPA05001430A (enExample)
NO (1) NO20051170L (enExample)
PA (1) PA8578001A1 (enExample)
PE (1) PE20040990A1 (enExample)
PL (1) PL375414A1 (enExample)
RU (1) RU2005102836A (enExample)
TW (1) TW200404532A (enExample)
WO (1) WO2004014386A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US7695731B2 (en) 2004-03-22 2010-04-13 Cordis Corporation Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
UA88008C2 (en) 2004-04-09 2009-09-10 Чугей Сейяку Кабусики Кайся Water-soluble prodrugs
AP2204A (en) * 2004-05-06 2011-02-07 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides.
BRPI0511800A (pt) * 2004-06-03 2008-01-15 Hoffmann La Roche tratamento com irinotecano (cpt-11) e um inibidor de egfr
RU2006146612A (ru) 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr)
KR100986945B1 (ko) * 2004-06-03 2010-10-12 에프. 호프만-라 로슈 아게 젬시타빈 및 egfr-억제제로의 치료
JP2008501708A (ja) * 2004-06-04 2008-01-24 スミスクライン ビーチャム (コーク) リミテッド がんの治療方法
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
EP2338488A1 (en) * 2006-05-26 2011-06-29 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
RU2325199C2 (ru) * 2006-06-20 2008-05-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ комбинированного лечения местно-распространенных форм рака шейки матки
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
JP2011503111A (ja) * 2007-11-12 2011-01-27 バイパー サイエンシズ,インコーポレイティド Parp阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
JP2014514359A (ja) * 2011-05-06 2014-06-19 メリマック ファーマシューティカルズ インコーポレーティッド 抗ErbB3剤を含む併用治療において有毒な薬物相互作用を予防するための方法
WO2021178789A1 (en) * 2020-03-06 2021-09-10 Deciphera Pharmaceuticals, Llc Methods of using rebastinib in the treatment of different cancerous disorders
CN118576601A (zh) * 2020-10-23 2024-09-03 和记黄埔医药(上海)有限公司 一种药物组合产品在制备用于治疗结肠癌的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287223B1 (en) * 1997-04-11 2001-09-11 Liechty, Ii Victor Jay Dulling prevention for sharp cutting edge of blade-opening arrowhead blades when in a closed in-flight position
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
US6281223B1 (en) * 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
KR20030068205A (ko) * 2001-01-09 2003-08-19 메르크 파텐트 게엠베하 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를사용하는 병용 요법

Similar Documents

Publication Publication Date Title
Tomek et al. Chemotherapy for malignant pleural mesothelioma: past results and recent developments
Carmichael The role of gemcitabine in the treatment of other tumours
RU2008118144A (ru) Комбинации иммуномодулирующих олигоодезоксинуклеотидов и способы их применения
RU2007134571A (ru) Комбинация и способы введения терапевтических средств и комбинированной терапии
JP2012523435A5 (enExample)
JP2004525950A5 (enExample)
RU2011145773A (ru) Ингибиторы 1 киназы контрольной точки клеточного цикла для усиления днк-повреждающих агентов
RU2012156958A (ru) ПРОИЗВОДНЫЕ ТИЕНО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ РАКА
JP2010514787A5 (enExample)
JP2017025090A5 (enExample)
MX2009012155A (es) Combinación farmacéutica sinérgica para el tratamiento de cáncer.
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
JP2011522773A5 (enExample)
Grünwald et al. Development of the epidermal growth factor receptor inhibitor Tarceva™(OSI-774)
JP2006500346A5 (enExample)
RU2006122350A (ru) Комбинированная химиотерапия
NO20033910L (no) Fremgangsmåte og doseringsform for behandling av tumorer ved administreringav tegafur, uracil, folinsyre, paclitaxel og karboplatin
AR040792A1 (es) Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
JP2023533937A5 (enExample)
JP2006502132A5 (enExample)
JP2007277240A5 (enExample)
Punt New drugs in the treatment of colorectal carcinoma
RU2008148597A (ru) Фармацевтические комбинации
JP2003526667A5 (enExample)
TW200603804A (en) Treatment with irinotecan (cpt-11) and an EGFR-inhibitor